149 related articles for article (PubMed ID: 36708563)
21. Ghrelin gene polymorphism as a genetic biomarker for prediction of therapy induced clearance in Egyptian chronic HCV patients.
Hamdy M; Kassim SK; Khairy E; Maher M; Mansour KA; Albreedy AM
Gene; 2018 Apr; 649():74-79. PubMed ID: 29374597
[TBL] [Abstract][Full Text] [Related]
22. Plasma cell-free DNA integrity index and hepatocellular carcinoma treated or not with direct-acting antivirals: A case-control study.
Kamal MM; Abdelaziz AO; El-Baz HN; Mohamed GM; Saleh SS; Nabeel MM; Elbaz TM; Lithy R; Shousha HI
Arab J Gastroenterol; 2022 Feb; 23(1):39-44. PubMed ID: 35120838
[TBL] [Abstract][Full Text] [Related]
23. TLL1 variants do not predict hepatocellular carcinoma development in HCV cirrhotic patients treated with direct-acting antivirals.
Degasperi E; Galmozzi E; Facchetti F; Farina E; D'Ambrosio R; Soffredini R; Iavarone M; Lampertico P
J Viral Hepat; 2019 Oct; 26(10):1233-1236. PubMed ID: 31177595
[TBL] [Abstract][Full Text] [Related]
24. Hepatocellular carcinoma recurrence in hepatitis C virus-related cirrhosis treated with direct-acting antivirals: a case-control study.
Adhoute X; Penaranda G; Raoul JL; Sellier F; Castellani P; Oules V; Perrier H; Lefolgoc G; Pol B; Campanile M; Bayle O; Beaurain P; Monnet O; Bourlière M
Eur J Gastroenterol Hepatol; 2018 Apr; 30(4):368-375. PubMed ID: 29384796
[TBL] [Abstract][Full Text] [Related]
25. Association of MicroRNA 196a and 499 Polymorphisms with Development of Cirrhosis and Hepatocellular Carcinoma Post-HCV Infection in Egyptian Patients.
Fteah AM; Ahmed AI; Mosaad NA; Hassan MM; Mahmoud SH
Asian Pac J Cancer Prev; 2019 Nov; 20(11):3479-3485. PubMed ID: 31759375
[TBL] [Abstract][Full Text] [Related]
26. Correlation Between Vascular Endothelial Growth Factor and Long-Term Occurrence of HCV-Related Hepatocellular Carcinoma After Treatment with Direct-Acting Antivirals.
Ramadan HK; Meghezel EM; Abdel-Malek MO; Askar AA; Hetta HF; Mahmoud AA; Abdel-Aal AM
Cancer Invest; 2021 Sep; 39(8):653-660. PubMed ID: 34224250
[TBL] [Abstract][Full Text] [Related]
27. Direct acting antivirals treatment for hepatitis C virus infection does not increase the incidence of de novo hepatocellular carcinoma occurrence: Results from an Italian real-life cohort (LINA cohort).
Buonomo AR; Scotto R; Coppola C; Pinchera B; Viceconte G; Rapillo CM; Staiano L; Saturnino M; Scarano F; Portunato F; Pisaturo M; De Pascalis S; Martini S; Tosone G; Nappa S; Coppola N; Gentile I
Medicine (Baltimore); 2020 Feb; 99(6):e18948. PubMed ID: 32028404
[TBL] [Abstract][Full Text] [Related]
28. Hepatocellular Carcinoma after Achievement of Sustained Viral Response with Daclatasvir and Asunaprevir in Patients with Chronic Hepatitis C Virus Infection.
Ida H; Hagiwara S; Kono M; Minami T; Chishina H; Arizumi T; Takita M; Yada N; Minami Y; Ueshima K; Nishida N; Kudo M
Dig Dis; 2017; 35(6):565-573. PubMed ID: 29040989
[TBL] [Abstract][Full Text] [Related]
29. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
Cabibbo G; Celsa C; Calvaruso V; Petta S; Cacciola I; Cannavò MR; Madonia S; Rossi M; Magro B; Rini F; Distefano M; Larocca L; Prestileo T; Malizia G; Bertino G; Benanti F; Licata A; Scalisi I; Mazzola G; Di Rosolini MA; Alaimo G; Averna A; Cartabellotta F; Alessi N; Guastella S; Russello M; Scifo G; Squadrito G; Raimondo G; Trevisani F; Craxì A; Di Marco V; Cammà C;
J Hepatol; 2019 Aug; 71(2):265-273. PubMed ID: 30959157
[TBL] [Abstract][Full Text] [Related]
30. Patients with HIV and cirrhosis: the risk for hepatocellular carcinoma after direct-acting antivirals for hepatitis C virus.
Guardigni V; Toschi A; Badia L; Rosselli Del Turco E; Salsi E; Cristini F; Sighinolfi L; Fabbri G; Massari M; Cuomo G; Viale P; Verucchi G;
AIDS; 2021 Oct; 35(12):1967-1972. PubMed ID: 34101631
[TBL] [Abstract][Full Text] [Related]
31. Serum α-fetoprotein level at treatment completion is a useful predictor of hepatocellular carcinoma occurrence more than one year after hepatitis C virus eradication by direct-acting antiviral treatment.
Kuwano A; Yada M; Nagasawa S; Tanaka K; Morita Y; Masumoto A; Motomura K
J Viral Hepat; 2022 Jan; 29(1):35-42. PubMed ID: 34661320
[TBL] [Abstract][Full Text] [Related]
32. Complex Association of Virus- and Host-Related Factors with Hepatocellular Carcinoma Rate following Hepatitis C Virus Clearance.
Akuta N; Suzuki F; Sezaki H; Kobayashi M; Fujiyama S; Kawamura Y; Hosaka T; Kobayashi M; Saitoh S; Suzuki Y; Arase Y; Ikeda K; Kumada H
J Clin Microbiol; 2019 Jan; 57(1):. PubMed ID: 30381417
[TBL] [Abstract][Full Text] [Related]
33. The Impact of interferon lambda 3 Polymorphism on Hepato-Cellular Carcinoma Progression in Hepatitis C Virus Patients: Treatment-Naïve and Experienced.
Abd Elrahman M; Ibrahim MK; Khairy A; Yosry A; Zayed N; Tawefeek S; Barakat AZ; Elbatae H; Bader El Din NG
Asian Pac J Cancer Prev; 2023 Jan; 24(1):215-221. PubMed ID: 36708570
[TBL] [Abstract][Full Text] [Related]
34. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals.
Prenner SB; VanWagner LB; Flamm SL; Salem R; Lewandowski RJ; Kulik L
J Hepatol; 2017 Jun; 66(6):1173-1181. PubMed ID: 28161470
[TBL] [Abstract][Full Text] [Related]
35. Direct-acting antivirals for patients with chronic hepatitis C and hepatocellular carcinoma in Taiwan.
Chi CT; Chen CY; Su CW; Chen PY; Chu CJ; Lan KH; Lee IC; Hou MC; Huang YH
J Microbiol Immunol Infect; 2021 Jun; 54(3):385-395. PubMed ID: 31771822
[TBL] [Abstract][Full Text] [Related]
36. Impact of IL28B gene polymorphism on efficacy and safety of direct acting antivirals in hepatitis C Egyptian patients.
Ebid AIM; Ahmed OA; Agwa SH; Abdel-Motaleb SM; Hagag RS
Int J Clin Pharm; 2020 Aug; 42(4):1207-1216. PubMed ID: 32712884
[TBL] [Abstract][Full Text] [Related]
37. CD4/CD8 Ratio could be predictor of burden hepatocellular carcinoma in Egyptian chronic hepatitis C after combined sofosbuvir and daclatasvir therapy.
El Menshawy N; Hassan N; Khariza M; AlAshery H; Baghat M; Ashour R
Afr Health Sci; 2023 Mar; 23(1):198-212. PubMed ID: 37545943
[TBL] [Abstract][Full Text] [Related]
38. Association between Toll-Like Receptor 3 (TLR3) rs3775290, TLR7 rs179008, TLR9 rs352140 and Chronic HCV.
Mosaad YM; Metwally SS; Farag RE; Lotfy ZF; AbdelTwab HE
Immunol Invest; 2019 Apr; 48(3):321-332. PubMed ID: 30321082
[TBL] [Abstract][Full Text] [Related]
39. Hong Kong Liver Cancer Staging System Is Associated With Better Performance for Hepatocellular Carcinoma: Special Emphasis on Viral Etiology.
Liu PH; Hsu CY; Lee YH; Su CW; Hsia CY; Huang YH; Chiou YY; Lin HC; Huo TI
Medicine (Baltimore); 2015 Oct; 94(41):e1772. PubMed ID: 26469917
[TBL] [Abstract][Full Text] [Related]
40. Impact of direct-acting antivirals on early recurrence of HCV-related HCC: Comparison with interferon-based therapy.
Nishibatake Kinoshita M; Minami T; Tateishi R; Wake T; Nakagomi R; Fujiwara N; Sato M; Uchino K; Enooku K; Nakagawa H; Asaoka Y; Shiina S; Koike K
J Hepatol; 2019 Jan; 70(1):78-86. PubMed ID: 30336183
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
